Skip to search formSkip to main contentSkip to account menu

selumetinib

An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein… 
National Institutes of Health

Related topics

Related topics

6 relations
ARRY 142886Inhibition of Cell ProliferationMAP3K1 protein, humanNCIt Antineoplastic Agent Terminology

Broader (1)

AZD 6244

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma.
The extensive heterogeneity both between and within the medulloblastoma subgroups underscores a critical need for variant… 
2016
2016
High-Content Imaging Platform for Profiling Intracellular Signaling Network Activity in Living Cells
2016
2016
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
10503Background: PN in NF1 can cause substantial morbidity, and there are no approved medical therapies. In a phase I trial of… 
2015
2015
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
SummaryPurposeKRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway… 
2014
2014
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
10018 Background: Lack of functional neurofibromin in NF1 leads to dysregulated Ras and tumorigenesis. Selumetinib (AZD6244; ARRY… 
Review
2013
Review
2013
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
K-RAS accounts for 90% of RAS mutations in lung adenocarcinomas, the most commonly mutated oncogene in NSCLC, with mutations… 
2013
2013
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
8026 Background: KRAS mutations are present in 20% of NSCLC and are associated with primary resistance to erlotinib (E). KRAS… 
2013
2013
Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be… 
Review
2012
Review
2012
[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
2012
2012
Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).
3529 Background: The RAF/MEK/ERK and PI3K/AKT signaling pathways are commonly deregulated in CRC. Each can serve as a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)